Photo: J Studios/Getty Images
Future Cardia, a medical device company, announced an expanded collaboration with remote cardiac monitoring company, Artella Solutions.
Future Cardia is developing an implantable cardiac monitoring device designed to offer long-term ECG data for rhythm evaluation.
According to the company, it is currently under regulatory review and has not yet been cleared or approved by the FDA for commercial use.
The two companies first teamed up during Future Cardia’s pre-FDA phase by integrating Artella's active state monitoring platform with Future Cardia’s investigational implantable sensor to expedite the secure transfer of ECG data for examination.
Now, Future Cardia and Artella Solutions are assessing the integration of Artella's remote cardiac monitoring platform into Future Cardia’s data and workflow ecosystem.
Artella's device-agnostic patch and telemetry platform offers an opportunity to evaluate data transfer, interoperability and workflow optimization.
"Future Cardia is bringing an implantable solution to a market that urgently needs innovation," Sepand Moshiri, Artella Solutions cofounder and CEO, said in a statement.
"Artella and its holding company CorMedica Group were built to partner with technologies like this in which data, automation, clinical oversight, and Elite Customer Service can meaningfully change outcomes for patients and providers."
Future Cardia CEO, Jae Bang, said that the company was founded on the belief that long-term physiologic data can improve the understanding of cardiac health.
"Our collaboration with Artella represents an important step in exploring how implantable and external monitoring technologies can work together to advance data integration and clinical workflow capabilities," Bang said in a statement.
THE LARGER TREND
In 2024, Samsung spin-off Wellysis entered into a collaboration with Artella Solutions to introduce a remote heart monitoring service in the United States.
The service features Wellysis's FDA-approved ECG-based solution S-Patch, along with the S-Patch ExL device, which allows for an extended testing period of up to 14 days on a single coin battery.
Other companies in the cardiac monitoring space include AccurKardia and HeartBeam, which joined forces in April to make AccurKardia's ECG analysis software available on HeartBeam's devices.
The two companies claimed that the addition of AccurKardia’s device-agnostic automated ECG interpretation platform to HeartBeam’s device has the ability to deliver earlier and more precise management of heart health.
The HIMSS AI & Cybersecurity Virtual Forum is free to attend on Nov. 18. Learn more and register.
